Quantcast

Latest GenomeDx Biosciences Stories

2014-06-16 08:28:19

SAN DIEGO, June 16, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced that it has entered into a contractual agreement as a participating provider with Prime Health Services to provide diagnostic laboratory testing services. GenomeDx, which discovered and developed the Decipher® Prostate Cancer Classifier, will provide laboratory services, making the Decipher test available to members of the Prime Health network, which includes 9 million covered lives. Prime Health payors...

2014-05-20 16:26:25

Two Studies Presented at 2014 AUA Annual Meeting SAN DIEGO, May 20, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced the presentation of data showing that its Decipher® Prostate Cancer Classifier, a genomic test capable of predicting metastatic prostate cancer, was able to identify patients that may be spared of radiation therapy after prostate surgery who would have been otherwise classified as high risk based on current clinical practice guidelines. In a separate study,...

2014-05-16 08:26:14

SAN DIEGO, May 16, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced the launch of the Decipher® Portal Professional, a mobile app designed for iPad tablets that allows registered medical practitioners to use and understand genomic information about prostate cancer and how it can impact their clinical practice. It offers physicians the opportunity to explore Decipher clinical data on interactive graphs, engage in hands-on exploration of clinical use scenarios and learn more...

2014-05-14 08:30:35

Two new clinical utility studies of Decipher published in BJU International and Current Medical Research and Opinion SAN DIEGO, May 14, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced data from two new clinical utility studies demonstrating that Decipher® Prostate Cancer Classifier significantly changed treatment decisions and increased confidence in treatment decision-making for men considering adjuvant therapy following prostate surgery. The studies are being published...

2014-05-08 08:32:48

SAN DIEGO, May 8, 2014 /PRNewswire/ -- GenomeDx Biosciences announced today that the company's Decipher® Prostate Cancer Classifier will be featured in multiple sessions during the American Urological Association (AUA) Annual Meeting taking place May 16-21 in Orlando, FL. Two data presentations will detail validation studies supporting the use of Decipher to predict risk of metastasis in men following prostate surgery. Decipher has also been included in independent CME and educational...

2014-04-11 08:24:36

SAN DIEGO, April 11, 2014 /PRNewswire/ -- GenomeDx Biosciences announced today that two study abstracts for the company's genomic tests for prostate and bladder cancers have been selected as "Best Posters in a Poster Session" by conference organizers at the 29(th) Annual European Association of Urology Congress. The first poster presentation demonstrates the clinical validation of the Decipher® prostate cancer classifier for predicting treatment failure in men treated with...

2014-03-04 08:31:51

SAN DIEGO, March 4, 2014 /PRNewswire/ -- GenomeDx Biosciences announced that it will present today at the 34(th) Annual Cowen and Company Healthcare Conference at 4:30 p.m. ET in Boston, Massachusetts. Doug Dolginow, M.D., CEO of GenomeDx, will provide a progress update on the commercialization of its Decipher® test and an overview of the Company's product pipeline in urology. About Decipher® The Decipher Prostate Cancer Classifier is a genomic test that directly measures the...

2014-02-03 08:27:25

SAN DIEGO, Feb. 3, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced that it has entered into a contractual agreement to provide its Decipher(®) prostate cancer test to FEDMED Payors. FEDMED is a national provider network that covers over 40 million lives. The Decipher( )prostate cancer classifier directly measures a patient's biological risk of developing metastatic prostate cancer. GenomeDx, which discovered and developed the Decipher test, will provide laboratory services...

2014-01-30 08:31:31

Multiple Studies of Decipher Prostate Cancer Classifier Presented at 2014 ASCO Genitourinary Symposium SAN DIEGO, Jan. 30, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced new data demonstrating that its Decipher® Prostate Cancer Classifier, a genomic test capable of predicting the probability of developing metastatic prostate cancer, outperformed existing clinical risk factors for predicting biochemical failure and distant metastasis following radiation therapy. In addition,...


Word of the Day
penuche
  • A fudgelike confection of brown sugar, cream or milk, and chopped nuts.
'Penuche' is a variant of 'panocha,' a coarse grade of sugar made in Mexico. 'Panocha' probably comes from the Spanish 'panoja, panocha,' ear of grain.
Related